Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Approves Cephalon’s Nuvigil With Bolded Warning For Rash

Jun 18 2007

• By The Pink Sheet Daily

Related Content

Cephalon CEO Frank Baldino: An Interview With “The Pink Sheet” DAILY

Jan 09 2007

Cephalon’s Oncologic Treanda On Track For Q4 NDA Filing

Feb 13 2007

Nuvigil Draft Label Warning Includes Both Modafinil And Its Follow-On

Mar 30 2007

Cephalon Provigil Generics Settlements Under FTC Investigation

Aug 30 2006

Nuvigil May Be Further Delayed As FDA Reviews Side Effect Profile

Dec 07 2006

Nuvigil Gets Protection Until 2023 Under New Patent

Nov 09 2006

Sepsis Set Back: AstraZeneca CytoFab Development Will Be Delayed Two Years

Nov 03 2006

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window